Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Moodys
Baxter
Express Scripts
Accenture
Daiichi Sankyo
Cipla
US Army
Teva
McKinsey

Generated: January 22, 2018

DrugPatentWatch Database Preview

Mylan Institutional Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN INSTITUTIONAL, and when can generic versions of MYLAN INSTITUTIONAL drugs launch?

MYLAN INSTITUTIONAL has fifty-six approved drugs.

There is one US patent protecting MYLAN INSTITUTIONAL drugs.

Summary for Mylan Institutional
US Patents:1
Tradenames:49
Ingredients:47
NDAs:56

Drugs and US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional TESTOSTERONE ENANTHATE testosterone enanthate INJECTABLE;INJECTION 040647-001 Oct 5, 2009 AO RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional ROCURONIUM BROMIDE rocuronium bromide INJECTABLE;INJECTION 079199-001 Nov 26, 2008 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional FOMEPIZOLE fomepizole INJECTABLE;INJECTION 078639-001 Mar 3, 2008 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional MEFOXIN cefoxitin sodium INJECTABLE;INJECTION 050517-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional KETAMINE HYDROCHLORIDE ketamine hydrochloride INJECTABLE;INJECTION 076092-002 Dec 28, 2001 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional MEFOXIN cefoxitin sodium INJECTABLE;INJECTION 062757-002 Jan 8, 1987 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional SOTRADECOL sodium tetradecyl sulfate INJECTABLE;INJECTION 040541-001 Nov 12, 2004 RX No Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional DIMETHYL SULFOXIDE dimethyl sulfoxide SOLUTION;INTRAVESICAL 076185-001 Nov 29, 2002 AT RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional METHOCARBAMOL methocarbamol SOLUTION;IM-IV 204404-001 Dec 5, 2014 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Institutional EPIRUBICIN HYDROCHLORIDE epirubicin hydrochloride INJECTABLE;INJECTION 065371-001 Nov 28, 2007 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional RIMSO-50 dimethyl sulfoxide SOLUTION;INTRAVESICAL 017788-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Mylan Institutional SULFAMYLON mafenide acetate CREAM;TOPICAL 016763-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 ➤ Subscribe ➤ Subscribe
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 ➤ Subscribe ➤ Subscribe
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 ➤ Subscribe ➤ Subscribe
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 ➤ Subscribe ➤ Subscribe
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019677-001 Nov 6, 1991 ➤ Subscribe ➤ Subscribe
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019678-001 Nov 6, 1991 ➤ Subscribe ➤ Subscribe
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 ➤ Subscribe ➤ Subscribe
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MYLAN INSTITUTIONAL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 1 mg/vial, 2 mg/vial and 5 mg/vial ➤ Subscribe 12/27/2013
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 12/16/2011
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 9/24/2007
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
UBS
Cipla
Fish and Richardson
Boehringer Ingelheim
McKinsey
Moodys
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot